APCS and amyloidosis: As such, since we could not evaluate the precise tissue localisation of dezamizumab–SAP binding (I.e. amyloid deposits vs normal tissue), we cannot provide a complete PD characterisation of dezamizumab in patients with cardiac amyloidosis.